inclusion criteria: participant is willing and able to give written informed consent to participate in the study age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment able and willing to complete all the scheduled study procedures during the whole study follow-up period if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the final dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) mosaic-1 vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 55 days prior to visit 1 (documentation of receipt required) mosaic -1 vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time mosaic-2 participants have received two doses of covid-19 vaccines authorized in canada ≥6 months prior to study vaccine administration (documentation of receipt required)

inclusion criteria: participant is willing and able to give written informed consent to participate in the study age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment able and willing to complete all the scheduled study procedures during the whole study follow-up period if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the final dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) mosaic-1 vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 55 days prior to visit 1 (documentation of receipt required) mosaic -1 vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time mosaic-2 participants have received two doses of covid-19 vaccines authorized in canada ≥6 months prior to study vaccine administration (documentation of receipt required)

inclusion criteria: participant is willing and able to give written informed consent to participate in the study age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment able and willing to complete all the scheduled study procedures during the whole study follow-up period if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 57 days prior to visit 1 (documentation of receipt required), or vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time

inclusion criteria: participant is willing and able to give written informed consent to participate in the study age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment able and willing to complete all the scheduled study procedures during the whole study follow-up period if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 57 days prior to visit 1 (documentation of receipt required), or vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time

inclusion criteria: 1. participant is willing and able to give written informed consent to participate in the study 2. age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment 3. able and willing to complete all the scheduled study procedures during the whole study follow-up period 4. if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) 5. vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 57 days prior to visit 1 (documentation of receipt required), or 6. vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time

inclusion criteria: 1. participant is willing and able to give written informed consent to participate in the study 2. age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment 3. able and willing to complete all the scheduled study procedures during the whole study follow-up period 4. if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) 5. vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 57 days prior to visit 1 (documentation of receipt required), or 6. vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time

inclusion criteria: 1. participant is willing and able to give written informed consent to participate in the study 2. age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment 3. able and willing to complete all the scheduled study procedures during the whole study follow-up period 4. if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) 5. vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 27 days prior to visit 1 (documentation of receipt required), or 6. vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time

inclusion criteria: 1. participant is willing and able to give written informed consent to participate in the study 2. age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment 3. able and willing to complete all the scheduled study procedures during the whole study follow-up period 4. if female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine (please refer to the definition section for a description of child-bearing potential and adequate contraception) 5. vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized covid-19 vaccine in the 27 days prior to visit 1 (documentation of receipt required), or 6. vaccine naïve subgroups: have not received an authorized covid-19 vaccine at any time